• Sep 06 2024 This Week in Cardiology

  • 2024/09/06
  • 再生時間: 30 分
  • ポッドキャスト

Sep 06 2024 This Week in Cardiology

  • サマリー

  • Feedback on ABYSS and beta-blockers, more ESC recap, including SHAM-PVI, FINEARTS-HF, and RESHAPE HF2 trials are the topics John Mandrola, MD, discusses in today’s podcast.

    This podcast is intended for healthcare professionals only.

    To read a partial transcript or to comment, visit:

    https://www.medscape.com/twic

    I. Feedback on ABYSS

    Setbacks After Stopping Beta-Blockers

    https://www.medscape.com/viewarticle/setbacks-after-stopping-beta-blockers-2024a1000fv7

    Beta-Blockers Post-MI? No for Me, Even After the ABYSS Trial

    https://www.medscape.com/viewarticle/beta-blockers-post-mi-no-me-even-after-abyss-trial-2024a1000fva

    • ABYSS trial https://www.nejm.org/doi/full/10.1056/NEJMoa2404204
    • REDUCE AMI https://www.nejm.org/doi/full/10.1056/NEJMoa2401479
    • QOL paper REDUCE AMI https://doi.org/10.1093/ehjcvp/pvae062
    • Atenolol ED paper 10.1016/j.ehj.2003.08.016

    II. SHAM-PVI

    • JAMA SHAM-PVI paper https://jamanetwork.com/journals/jama/article-abstract/2823283
    • Gupta QOL paper https://pubmed.ncbi.nlm.nih.gov/33952593/

    III. FINEARTS HF

    Finerenone Benefits Heart Failure With Preserved EF

    https://www.medscape.com/viewarticle/finerenone-benefits-heart-failure-preserved-ef-2024a1000fza

    Topline Finerenone Results Point to Advance in Heart Failure

    https://www.medscape.com/viewarticle/topline-finerenone-results-point-advance-heart-failure-2024a1000fq2

    • FINEHEARTS -HF NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2407107
    • FIDELIO-DKD https://www.nejm.org/doi/full/10.1056/NEJMoa2025845
    • FIGARO-DKD https://www.nejm.org/doi/full/10.1056/NEJMoa2110956
    • Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF? https://doi.org/10.1016/j.jacc.2024.08.033

    IV. RESHAPE HF

    TEER in Functional MR: Data Deluge, but No Easy Answers

    https://www.medscape.com/viewarticle/teer-functional-mr-data-deluge-no-easy-answers-2024a1000fvg

    • Mitra FR https://www.nejm.org/doi/full/10.1056/NEJMoa1805374
    • COAPT https://www.nejm.org/doi/full/10.1056/NEJMoa1806640
    • RESHAPE- HF2 https://www.nejm.org/doi/full/10.1056/NEJMoa2314328
    • RESHAPE Subgroup paper https://doi.org/10.1016/j.jacc.2024.08.027

    You may also like:

    The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

    Questions or feedback, please contact news@medscape.net

    続きを読む 一部表示
activate_samplebutton_t1

あらすじ・解説

Feedback on ABYSS and beta-blockers, more ESC recap, including SHAM-PVI, FINEARTS-HF, and RESHAPE HF2 trials are the topics John Mandrola, MD, discusses in today’s podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. Feedback on ABYSS

Setbacks After Stopping Beta-Blockers

https://www.medscape.com/viewarticle/setbacks-after-stopping-beta-blockers-2024a1000fv7

Beta-Blockers Post-MI? No for Me, Even After the ABYSS Trial

https://www.medscape.com/viewarticle/beta-blockers-post-mi-no-me-even-after-abyss-trial-2024a1000fva

  • ABYSS trial https://www.nejm.org/doi/full/10.1056/NEJMoa2404204
  • REDUCE AMI https://www.nejm.org/doi/full/10.1056/NEJMoa2401479
  • QOL paper REDUCE AMI https://doi.org/10.1093/ehjcvp/pvae062
  • Atenolol ED paper 10.1016/j.ehj.2003.08.016

II. SHAM-PVI

  • JAMA SHAM-PVI paper https://jamanetwork.com/journals/jama/article-abstract/2823283
  • Gupta QOL paper https://pubmed.ncbi.nlm.nih.gov/33952593/

III. FINEARTS HF

Finerenone Benefits Heart Failure With Preserved EF

https://www.medscape.com/viewarticle/finerenone-benefits-heart-failure-preserved-ef-2024a1000fza

Topline Finerenone Results Point to Advance in Heart Failure

https://www.medscape.com/viewarticle/topline-finerenone-results-point-advance-heart-failure-2024a1000fq2

  • FINEHEARTS -HF NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2407107
  • FIDELIO-DKD https://www.nejm.org/doi/full/10.1056/NEJMoa2025845
  • FIGARO-DKD https://www.nejm.org/doi/full/10.1056/NEJMoa2110956
  • Why Have We Not Been Able to Demonstrate Reduced Mortality in Patients With HFmrEF/HFpEF? https://doi.org/10.1016/j.jacc.2024.08.033

IV. RESHAPE HF

TEER in Functional MR: Data Deluge, but No Easy Answers

https://www.medscape.com/viewarticle/teer-functional-mr-data-deluge-no-easy-answers-2024a1000fvg

  • Mitra FR https://www.nejm.org/doi/full/10.1056/NEJMoa1805374
  • COAPT https://www.nejm.org/doi/full/10.1056/NEJMoa1806640
  • RESHAPE- HF2 https://www.nejm.org/doi/full/10.1056/NEJMoa2314328
  • RESHAPE Subgroup paper https://doi.org/10.1016/j.jacc.2024.08.027

You may also like:

The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact news@medscape.net

Sep 06 2024 This Week in Cardiologyに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。